Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $472,590.00 in Stock
04:36am, Sunday, 19'th Apr 2026
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) COO Jeremy Chadwick sold 5,251 shares of the business's stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug
01:41pm, Tuesday, 14'th Apr 2026
Kymera Therapeutics shares jump after FDA grants Fast Track to KT-621 for eosinophilic asthma, spotlighting its first-in-class STAT6 degrader potential.
Kymera: 'Strong Buy' On Continued Success With KT-621 In Th2-Driven Disorders
03:12pm, Monday, 13'th Apr 2026
Kymera Therapeutics remains a "Strong Buy", driven by positive phase 1b data for KT-621 in atopic dermatitis and pipeline expansion. KT-621 achieved a mean 63% EASI reduction and 40% pruritus NRS redu
KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track de
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
01:06pm, Friday, 10'th Apr 2026
Kymera Therapeutics secures $45M as Gilead licenses KT-200, advancing a novel CDK2 degrader with potential in breast cancer and solid tumors.
SG Americas Securities LLC Grows Position in Kymera Therapeutics, Inc. $KYMR
05:03am, Monday, 06'th Apr 2026
SG Americas Securities LLC boosted its position in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) by 169.1% during the undefined quarter, according to the company in its most recent disclosure wit
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 14,640 Shares
04:48am, Friday, 03'rd Apr 2026
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) COO Jeremy Chadwick sold 14,640 shares of the business's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold a
Kymera Therapeutics (NASDAQ:KYMR) Director Elena Ridloff Sells 7,400 Shares of Stock
04:48am, Friday, 03'rd Apr 2026
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) Director Elena Ridloff sold 7,400 shares of the business's stock in a transaction on Tuesday, March 31st. The stock was sold at an average pr
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 7,600 Shares of Stock
04:47am, Friday, 03'rd Apr 2026
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) COO Jeremy Chadwick sold 7,600 shares of the firm's stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
07:05am, Wednesday, 01'st Apr 2026
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.
Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621's compelling oral profile
Nextech Trims Kymera at a Recent High — think Foolishly before acting.
11:37am, Thursday, 19'th Mar 2026
Sold 62,013 shares of Kymera Therapeutics; estimated transaction value $4.19 million (based on mean unadjusted close for the quarter). The quarter-end position value increased by $2.41 million, reflec
Bamco Inc. NY Takes Position in Kymera Therapeutics, Inc. $KYMR
03:36am, Tuesday, 17'th Mar 2026
Bamco Inc. NY purchased a new stake in Kymera Therapeutics, Inc. (NASDAQ: KYMR) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The
Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
01:12pm, Thursday, 12'th Mar 2026
Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine
